Related Experiment Video

Updated: Jun 6, 2025

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.0K

Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia

Kengo Ayabe1, Tomoyoshi Komiyama2, Hiroyuki Takekawa1

  • 1Cardiovascular Center, Miyazaki Medical Association Hospital, Miyazaki 880-2102, Japan.

Medicina (Kaunas, Lithuania)
|November 27, 2024
PubMed

Insights

Landiolol effectively controls heart rate in atrial fibrillation (AF) but may be less effective for atrial tachycardia (AT) in patients with left ventricular dysfunction. Dosage adjustments may be needed for AT management.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Landiolol, an ultra-short-acting beta-1 selective blocker, shows promise in heart rate control for atrial tachyarrhythmias.
  • Previous studies suggest landiolol is more effective than digoxin in patients with left ventricular dysfunction.
  • The impact of different atrial tachyarrhythmia types on landiolol's efficacy is not well-established.

Purpose of the Study:

  • To evaluate the effectiveness and safety of landiolol in patients with tachycardiac atrial fibrillation (AF) and atrial tachycardia (AT).
  • To assess landiolol's efficacy across different left ventricular ejection fraction statuses.
  • To determine if landiolol's effectiveness varies between AF and AT in patients with reduced left ventricular function.

Main Methods:

  • A study involving 44 patients with reduced left ventricular function.
  • Evaluation of landiolol's efficacy and safety in managing tachycardiac AF and tachycardiac atrial flutter/AT.
  • Comparison of heart rate control in patients with AF versus AT.

Main Results:

  • Landiolol demonstrated effectiveness in managing AF patients, including those with preserved or mid-range ejection fraction.
  • Heart rate control in patients with atrial tachycardia (AT) using landiolol appeared more challenging with similar dosages.
  • The study assessed both efficacy and safety profiles of landiolol in the studied population.

Conclusions:

  • Landiolol is effective for heart rate management in atrial fibrillation (AF) patients with varying degrees of left ventricular function.
  • Managing heart rate in atrial tachycardia (AT) with landiolol may require dosage adjustments compared to AF.
  • Further research may be needed to optimize landiolol dosing strategies for specific atrial tachyarrhythmia types.

Keywords:
HFmrEFHFpEFHFrEFlandiololβ-blocker

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.3K
Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents10:53

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents

Published on: July 3, 2013

20.4K

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
780
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
707
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
407
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
910
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316